Equity research - Bayer ag: the growth path for a pharma titan

One of Bayer AG’s strongest assets and operational flagship across the globe has been its pharmaceutical division, which comprisesroughly40% of total sales of the group, as of 2020. However, it is now dealing with major business shifts which undermine its the medium-term growth prospects, as its two...

Full description

Bibliographic Details
Main Author: Santos, Rui Miguel Pinto dos (author)
Format: masterThesis
Language:eng
Published: 2022
Subjects:
Valuation
Finance
Equity research
Pharmaceutical industry
Dcf valuation
Crop science
Consumer health
Bayer ag
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
Online Access:http://hdl.handle.net/10362/140596
Country:Portugal
Oai:oai:run.unl.pt:10362/140596

Internet

http://hdl.handle.net/10362/140596

Similar Items